Feature | Thrombectomy Devices | June 12, 2015

Ultrasound to Breakup STEMI Causing Clots in Heart Attack Patients

Breakthrough research at ASE demonstrates contrast ultrasound may help restore some blood flow in myocardial infarction patients

STEMI, ultrasound to treat heart attacks, ultrasound to treat STEMI

June 12, 2015 - Researchers presented data at the 2015 American Society of Echocardiography (ASE) meeting in June showing intravenous microbubbles combined with transthoracic ultrasound can help restore blood flow to the heart muscle in acute ST-segment elevation myocardial infarction (STEMI), potentially preserving heart function in these patients.  This sonothrombolysis method uses ultrasound to burst ultrasound contrast bubbles inside the STEMI-causing clot, which creates micro-channels for blood flow within the clot.  

This method also may help reduce the "no-reflow"phenomena following percutaneous coronary intervention (PCI). This is believed to be caused by stenting sending clot emboli downstream into the capillaries. Using ultrasound as a therapy device also has advantages of imaging the anatomy simultaneously. 
 
Nearly 250,000 people experience STEMI heart attacks annually and one of the most important factors for recovery is quick treatment to reduce blockages and restore blood flow to prevent muscle death. While this sonothrombolysis technique has previously been studied in animals, this is the first study to test the method in humans.
 
"This is a breakthrough, first-in-humans study in patients with acute myocardial infarction that has the potential to revolutionize the treatment of these patients and other acute thrombotic diseases such as stroke and deep venous thrombosis," said senior author Wilson Mathias, Jr., M.D., University of Sí£o Paulo Medical School in Sí£o Paulo, Brazil.  
 
The research team used a standard diagnostic ultrasound transducer to apply high mechanical index impulses during a continuous infusion of Definity (produced by Lantheus) microbubble contrast agent in a large emergency room setting. The combination of ultrasound and echo contrast were used both immediately prior to and immediately following emergent PCI.  Those patients who were randomized to one of two sonothrombolysis groups showed both higher recanalization rates at initial angiography and improving cardiac function. Most importantly, no patient deaths were experienced and door-to-dilation times were not affected, demonstrating both safety and feasibility for this technique. 
 
Ultrasound contrast is composed of microscopic lipid spheres that are injected into the patient's bloodstream.  The bubbles return the ultrasonic sound waves used to form an image and enhance the blood.  The ultrasonic waves also shatter the bubbles and it is the physics of the cavitaion caused by breaking bubbles that enables the microscopic breakdown of the thrombus. 
 
Researchers on the study, "Safety and Feasibility of Diagnostic Ultrasound High Mechanical Index Impulses in Restoring Epicardial Flow in Acute ST Segment Elevation Myocardial Infarction in Humans," included Bruno Garcia Tavares, Jeane M. Tsutsui, Miguel Osmar Aguiar, Diego Garcia, Mucio T. Oliveira, Alexandre Soeiro, Jose C. Nicolau, Pedro Lemos, Roberto Kalil, and Wilson Mathias, Jr. of Heart Institute (InCor) - University of Sí£o Paulo Medical School in Sí£o Paulo, Brazil; and  Thomas R. Porter of the University of Nebraska Medical Center in Omaha.
 
In future technology sessions at ASE, there were discussions on developing new echo contrast agents with embedded lytic therapy in the lipid shell to deliver lyics only to the targeted anatomy.   
 
For more information: www.asescientificsessions.org
 

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init